Neuraminidase inhibitors for preventing and treating influenza in healthy adults

Abstract

Analysis 1.1. Comparison 1 NI versus placebo for prophylaxis, Outcome 1 Influenza-like illness.. .. .. .. Analysis 1.2. Comparison 1 NI versus placebo for prophylaxis, Outcome 2 Influenza (symptomatic).. .. .. . Analysis 1.3. Comparison 1 NI versus placebo for prophylaxis, Outcome 3 Influenza (symptomatic and asymptomatic). Analysis 1.4. Comparison 1 NI versus placebo for prophylaxis, Outcome 4 Influenza (asymptomatic).. .. .. Analysis 1.5. Comparison 1 NI versus placebo for prophylaxis, Outcome 5 Adverse events-nausea.. .. .. . Analysis 1.6. Comparison 1 NI versus placebo for prophylaxis, Outcome 6 Adverse events-vomiting.. .. .. Analysis 1.7. Comparison 1 NI versus placebo for prophylaxis, Outcome 7 Adverse events-diarrhoea.. .. .. Analysis 1.8. Comparison 1 NI versus placebo for prophylaxis, Outcome 8 Adverse events-abdominal pain.. .. Analysis 1.9. Comparison 1 NI versus placebo for prophylaxis, Outcome 9 Adverse events-others.. .. .. .

Neuraminidase inhibitors for preventing and treating influenza in healthy adults

“…At the bottom of Tamiflu.com webpages is a bold-face note: 06 to 1.35)." (22) IFLU in any illness caused by agents other than 254 influenza viruses Types A and B." (20) Japan PMDA: "Tamiflu has no effect against infections except those caused by influenza A and B viruses."…”

Influenza control in Australian prison settings: Cost ‐ benefit analysis of major strategies

“…Neuraminidase inhibitors represent a new class of antivirals specific for influenza A and B, with few side-effects. They have been shown to be effective in prophylaxis and treatment of influenza (Hayden et al, 1997;Jefferson, Dimicheli, Deeks, & Rivetti, 2001;National Institute for Clinical Excellence, 2000;O'Brien, Goeree, Blackhouse, Smeja, & Loeb, 2003). Used as prophylaxis prior to an influenza epidemic, a difference in infection rates from 73% in a placebo group to 13% in individuals on zanamivir has been documented.…”

Zum Einsatz von Influenza-Schnelltests zur individuellen Diagnose

“…Die klinischen Studien insbesondere zu den NH haben gezeigt, dass der Erfolg einer antiviralen Therapie bei Personen mit schwerem Krankheitsbild, die zumindest die »Influenza-typischen Symptome« zeigen, besonders groß ist (5,9). Dies wird bei den Empfehlungen für die Auswahl der für eine Behandlung in Frage kommenden Personen berücksichtigt, so dass nur Influenza-typische Erkrankungen in einem frühen Stadium für eine mögliche Behandlung ausgewählt und im Folgenden betrachtet werden.…”